Neoantigens are generated via structural alterations to the proteome of cancer cells through amino acid substitution,5 post-translational modifications,6 and other mechanisms.7 These non-self peptides, which can be loaded on MHC-I for presentation, can potentially engage with TCRs on T cells.8 Therefore, CD8+ T cells displaying the cognate TCR are well positioned to specifically recognize and respond to neoantigen-presenting cancer cells to promote an anti-cancer immune response.7 In many instances, these mechanisms are central to eliminate the emergence of cancerous cells. Here, CD8A is linked to cancer.